Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug could cut blood transfusions for MDS patients

NCT ID NCT06499285

Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This phase 3 trial tests elritercept, a drug given as a shot every 4 weeks, to see if it can help adults with a bone marrow disease called MDS go without red blood cell transfusions for at least 8 weeks. About 225 participants with very low- to intermediate-risk MDS who need regular transfusions will be randomly assigned to receive elritercept or a placebo. The study will also check for longer-term transfusion independence and monitor safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
elritercept (KER-050, TAK-226)
What this could lead to
If successful, this drug could help many people with MDS need fewer blood transfusions, improving their quality of life.
What could go wrong
This is a phase 3 trial, but results are not guaranteed. The drug may not work for everyone, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 225 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

May 2032

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information and/or protected personal data in accordance with national and local study participant data protections and privacy regulations. * Male or female greater than or equal to (≥)18 years of age at the time of signing informed consent. * Diagnosis of MDS with or without RS (as determined in an evaluable bone marrow aspirate, read by an independent central reader to confirm diagnosis at Screening) according to the World Health Organization 2016 classification that meets the International Prognostic Scoring System-Revised (IPSS-R) classification of very low, low, or intermediate risk disease. * Transfusion dependence assessed in the 16 weeks immediately preceding randomization in two 8-week blocks, classified as either: a. Low-transfusion burden (LTB), defined as 4 to 7 red blood cells (RBC) units per 16 weeks; or b. High-transfusion burden (HTB), defined as ≥8 RBC units per 16 weeks; and c. For all participants: i. Only transfusion events for a pretransfusion hemoglobin (Hgb) lesser than (\<)10 grams per deciliter (g/dL) are counted toward eligibility; ii. At least 1 transfusion event in each 8-week period and a minimum of 2 transfusion events separated by ≥7 days within the 16-week period immediately preceding randomization; and iii. No consecutive 56-day period can be RBC transfusion-free during the 16-week period immediately preceding randomization. * Refractory or intolerant to prior erythropoiesis-stimulating agent (ESA) treatment (discontinued ≥4 weeks before randomization), or unlikely to respond to ESA treatment, defined as follows: a. Refractory to prior ESA treatment: documentation of nonresponse or a response that was no longer maintained with a prior ESA-containing regimen, either as a single agent or combination (e.g., with granulocyte colony-stimulating factor \[G-CSF\]); ESA regimen must have been either: i. Recombinant human erythropoietin (EPO) ≥40,000 international units per week (IU/week) for ≥8 doses or equivalent; or ii. Darbepoetin alpha ≥500 micrograms (μg) every 3 weeks for ≥4 doses or equivalent. b. Intolerant to prior ESA treatment: documentation of discontinuation of a prior ESA-containing regimen, either as a single agent or combination (e.g., with G-CSF), at any time after introduction due to intolerance or an AE. c. Unlikely to respond to ESA treatment: low chance of response to ESA based on an endogenous serum EPO level greater than (\>)200 units per liter (U/L). * Less than 5% blasts in an evaluable bone marrow aspirate collected at Screening, read by an independent central reader. * Eastern Cooperative Oncology Group performance status of 0 to 2. * Females of childbearing potential and sexually active males must agree to use highly effective methods of contraception. * In the opinion of the Investigator, the participant is able and willing to comply with the requirements of the protocol (e.g., all study procedures, return for follow-up visits). Exclusion Criteria: * Del(5q) MDS or therapy-related (secondary) MDS. * Anemia due to any other known cause (e.g., thalassemia, hemolytic anemia, bleeding events, or deficiency of iron, B12, and/or folate). * Receipt of RBC transfusion for any reason(s) other than underlying MDS within 16 weeks before randomization. * Clinically significant cardiovascular disease defined as: 1. New York Heart Association heart disease class III or IV; 2. Fridericia corrected QT (QTcF) interval \>500 milliseconds during Screening; 3. Presence of uncontrolled hypertension defined as mean systolic blood pressure ≥160 millimeters of mercury (mm Hg) or diastolic blood pressure ≥100 mm Hg during Screening; or 4. Uncontrolled arrhythmia, myocardial infarction, or unstable angina within 6 months before Screening. * Known ejection fraction \<35%, confirmed by a local echocardiogram performed during Screening, or a previously performed echocardiogram if collected within 6 months before Screening. * Child-Pugh class C hepatic impairment. * Stroke, deep vein thrombosis, or pulmonary embolism within 6 months before Screening. * Any known history of acute myeloid leukemia (AML). * Prior history of malignancies, other than MDS, unless participant has been free of the disease (including completion of any treatment, including maintenance, for prior malignancy) for ≥ 5 years. However, participants with a history or concurrent diagnosis of the following conditions are allowed if not requiring systemic therapy: 1. Basal or squamous cell carcinoma of the skin; 2. Carcinoma in situ of the cervix; 3. Carcinoma in situ of the breast; and/or 4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis \[TNM\] clinical staging system). * History of solid organ or bone marrow transplantation. * Active infection requiring intravenous treatment (e.g., antibiotics, antifungals, or antivirals) within 28 days, or oral treatment within 14 days before randomization. * History of or known active chronic infection with HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV). Participants without known positive history of HIV, HBV, and/or HCV do not require further testing, unless testing is mandated per local guidelines. * Body mass index ≥ 40 kilograms per meter square (kg/m\^2). * Major surgery within 28 days before randomization. * History of allergy/anaphylaxis to investigational medicinal product (IMP) excipients (refer to the current elritercept IB for a list of excipients) or recombinant proteins. * Prior use of elritercept, luspatercept, or sotatercept. * Prior use of hypomethylating agents (HMAs), isocitrate dehydrogenase inhibitor, lenalidomide, imetelstat, or immunosuppressive therapy given for treatment of MDS. * Iron chelation therapy initiated within 8 weeks before randomization. Participants on stable doses of iron chelation therapy for ≥ 8 weeks are allowed. * Vitamin B12 or folate therapy initiated within 4 weeks before randomization. Participants on stable replacement doses for ≥ 4 weeks and without ongoing concurrent vitamin B12 or folate deficiency are allowed. * Androgen use within 8 weeks before randomization. Participants on stable androgen dosing for hypogonadism for ≥ 8 weeks are allowed. * High-dose corticosteroid use within 4 weeks before randomization. Participants on stable chronic steroid doses of prednisone lesser than or equal to (≤) 10 mg/day or corticosteroid equivalent for ≥ 4 weeks are allowed.10 mg/day or corticosteroid equivalent for ≥ 4 weeks are allowed. * Treatment with any investigational drug within 28 days before Screening or, if the half-life of the product is known, within 5 times the half-life before Screening, whichever is longer. * Ongoing participation in another interventional clinical study. * Serum EPO level \>500 U/L. * Platelet count ≥450 × 10\^9/L or ≤25 × 10\^9/L. * Absolute neutrophil count ≤ 500/µL. * Serum aspartate aminotransferase or alanine aminotransferase ≥3 × the upper limit of normal (ULN). * Total bilirubin ≥2 × ULN unless attributable to Gilbert's syndrome. * Ferritin ≤ 50 micrograms per litre (μg/L). * Folate ≤2.0 nanograms per milliliter (ng/mL). * Vitamin B12 ≤200 picograms per milliliter (pg/mL). * Estimated glomerular filtration rate \<30 milliliters per minute per 1.73 meter square (mL/min/1.73m\^2) as determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Collaboration equation. * Pregnant or lactating female. * Any other condition not specifically noted above that, in the opinion of the Investigator, would preclude the participant from participating in the study or could confound interpretation of data from the study. * Investigational site staff members directly involved in the conduct of the study and site staff members otherwise supervised by the Investigator, employees of the Sponsor or contract research organization (CRO) directly involved in the conduct of the study, or immediate family members (defined as a spouse, parent, child, or sibling, whether biological or legally adopted). * For Participants in France: Persons under court protection, persons not affiliated with a social security system, and protected adults (per applicable French law \[Art. L. 1121-6, Art. L. 1121-8, Art. L. 1121-8-1\]).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myelodysplastic syndromes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myelodysplastic syndromes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    177 sites in 26 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • A-rebro University Hospital, Hematology Department

    NOT_YET_RECRUITING

    Örebro, A-rebro County, 70185, Sweden

  • AO Ordine Mauriziano

    NOT_YET_RECRUITING

    Turin, Piedmont, 10128, Italy

  • Aberdeen Royal Infirmary

    RECRUITING

    Aberdeen, Aberdeen City, AB25 2ZN, United Kingdom

  • Adana City Hospital

    NOT_YET_RECRUITING

    Adana, 01370, Turkey (Türkiye)

  • Addenbrooke's Hospital

    RECRUITING

    Cambridge, CB2 0QQ, United Kingdom

  • Alberts Cellular Therapy

    RECRUITING

    Pretoria, 0181, South Africa

  • Alfred Health

    NOT_YET_RECRUITING

    Melbourne, Victoria, 3004, Australia

  • All India Institute of Medical Science

    RECRUITING

    New Delhi, National Capital Territory of Delhi, 110029, India

  • Americas Institute

    RECRUITING

    Rio de Janeiro, 22775-001, Brazil

  • Amrita Institute of Medical Sciences

    NOT_YET_RECRUITING

    Ernākulam, Kerala, 682041, India

  • Anglo American Clinic

    NOT_YET_RECRUITING

    Lima, La Molina, 15023, Peru

  • Ankara Etlik City Hospital

    NOT_YET_RECRUITING

    Ankara, 06170, Turkey (Türkiye)

  • Ankara University Medical Faculty Cebeci Hospital

    NOT_YET_RECRUITING

    Ankara, 06600, Turkey (Türkiye)

  • Antalya Education and Training Hospital

    NOT_YET_RECRUITING

    Antalya, 07100, Turkey (Türkiye)

  • Aou Delle Marche

    NOT_YET_RECRUITING

    Ancona, AN, 60126, Italy

  • Apollo Hospital International Ltd

    RECRUITING

    Ahmedabad, Gujarat, 382428, India

  • Archet 1 and 2 hospital

    RECRUITING

    Nice, 06200, France

  • Asan Medical Center

    RECRUITING

    Seoul, 05505, South Korea

  • Banphaeo General Hospital

    RECRUITING

    Bangkok, 74210, Thailand

  • Beaumont Hospital

    RECRUITING

    Dublin, D05 DK31, Ireland

  • Box Hill Hospital

    RECRUITING

    Box Hill, Victoria, 3128, Australia

  • Capital Haematology Hospital

    RECRUITING

    Durban, 4091, South Africa

  • Careggi University Hospital

    RECRUITING

    Florence, 50134, Italy

  • Catalan Institute of Oncology, Hospital Duran i Reynals, Department of Clinical Hematology

    RECRUITING

    L'Hospitalet de Llobregat, Girona, 08908, Spain

  • Center for Clinical Studies and Medical Research (CECIM)

    RECRUITING

    Santiago, 8320000, Chile

  • Cepho- Fmabc

    RECRUITING

    Santo André, São Paulo, 09060-650, Brazil

  • Chaim Sheba Medical Center, Department of Hematology, Myelodysplastic Syndromes Center

    RECRUITING

    Ramat Gan, 5266202, Israel

  • Chang Bing Show Chwan Memorial Hospital

    RECRUITING

    Changhua, Changhua County, 50544, Taiwan

  • Changhua Christian Hospital

    RECRUITING

    Changhua, Changhua County, 500209, Taiwan

  • Charite Universitatsmedizin Berlin

    NOT_YET_RECRUITING

    Berlin, 12203, Germany

  • Charlotte Maxeke Johannesburg Academic Hospital, Hemophilia Comprehensive Care Center

    RECRUITING

    Johannesburg, 2193, South Africa

  • Christian Medical College

    RECRUITING

    Vellore, Tamil Nadu, 632004, India

  • Christian Medical College, Ludhianana

    RECRUITING

    Ludhiana, Punjab, 380006, India

  • Churchill Hospital

    RECRUITING

    Oxford, OX3 7LE, United Kingdom

  • City of Hope

    RECRUITING

    Duarte, California, 91010, United States

  • Cleveland Clinic - Cleveland

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Clinic Inmunocel

    RECRUITING

    Santiago, 7580206, Chile

  • Clinical Hospital Of The Ministry Of Internal Affairs And Administration With Warmia And Mazury Oncology Centre In Olsztyn, Clinical Department of Hematology and Internal Medicine with Bone Marrow Transplantation Center

    RECRUITING

    Olsztyn, 10-228, Poland

  • Clinical Institute Humanitas, IRCCS

    RECRUITING

    Rozzano, 20089, Italy

  • Clinical Research Alliance NY

    RECRUITING

    Westbury, New York, 11590, United States

  • Comprehensive Cancer Centers of Nevada

    RECRUITING

    Henderson, Nevada, 89169, United States

  • Cork University Hospital

    RECRUITING

    Cork, T12 DC4A, Ireland

  • Daniel Alcides Carrion National Hospital

    NOT_YET_RECRUITING

    Bellavista, 07016, Peru

  • Dr. Guillermo Grant Benavente - Concepcion Regional Hospital

    RECRUITING

    Concepción, Biobio, 4070356, Chile

  • Dr. Pencho Georgiev - Outpatient Center for Individual Practice for Specialized Medical Care in Internal Medicine and Clinical Hematology (EOOD)

    RECRUITING

    Plovdiv, 4002, Bulgaria

  • Edgardo Rebagliati Martins National Hospital

    NOT_YET_RECRUITING

    Lima, Jesus Maria, 15073, Peru

  • Fejer County St. Gyorgy University Teaching Hospital, Department of Internal Medicine III, Hematology

    RECRUITING

    Székesfehérvár, H-8000, Hungary

  • Flinders Medical Centre

    RECRUITING

    Adelaide, South Australia, 5042, Australia

  • Foundation PTV - Polyclinic Tor Vergata

    RECRUITING

    Rome, 00133, Italy

  • FundaAAo Doutor Amaral Carvalho

    NOT_YET_RECRUITING

    Jaú, São Paulo, 17210-080, Brazil

  • Gabrail Cancer Center Research

    RECRUITING

    Canton, Ohio, 44718, United States

    Contact Email: •••••@•••••

  • Glan Clwyd Hospital

    NOT_YET_RECRUITING

    Rhyl, Denbighshire, LL18 5UJ, United Kingdom

  • Granda Ospedale Metropolitano 'Bianchi-Melacrino-Morelli'

    RECRUITING

    Reggio Calabria, 89133, Italy

  • Hadassah Medical Center, Department of Hematology

    RECRUITING

    Jerusalem, 9112001, Israel

  • Haemalife

    RECRUITING

    Cape Town, 7580, South Africa

  • Heamto Oncology Clinic Ahmedabad Pvt. Ltd.

    RECRUITING

    Ahmedabad, Gujarat, 380009, India

  • Hospital A.C.Camargo ("Antonio Prudente" Foundation)

    RECRUITING

    São Paulo, 01509-900, Brazil

  • Hospital Mae de Deus, Clinical Research Unit - Cancer Institute

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90110-270, Brazil

  • Hospital of Lithuanian University of Health Sciences Kauno Klinikos

    RECRUITING

    Kaunas, LT-50161, Lithuania

  • Hosptial Erasto Gaertner

    RECRUITING

    Curitiba, Paraná, 81520-060, Brazil

  • IC La Serena Research

    RECRUITING

    La Serena, Coquimbo Region, 1720430, Chile

  • ILCC. Illinois Cancer Centers

    RECRUITING

    Peoria, Illinois, 61645, United States

  • IPOR: Peruvian Institute of Oncology & Radiotherapy

    RECRUITING

    Lima, San Isidro Lima, 02002, Peru

  • IUCT-Oncopole

    RECRUITING

    Toulouse, 31059, France

  • Insel Gruppe AG, University Clinic for Hematology and Central Hematological Laboratory

    NOT_YET_RECRUITING

    Bern, 3010, Switzerland

  • Institute of Cancer Research and Treatment of Candiolo

    RECRUITING

    Turin, 10060, Italy

  • Institute of Hematology and Blood Transfusion, Division of Training and Development

    NOT_YET_RECRUITING

    Prague, 12800, Czechia

  • Instituto Joinvilense de Hematologia e Oncologia

    NOT_YET_RECRUITING

    Joinville, Santa Catarina, 89201-260, Brazil

  • Karolinska University Hospital

    RECRUITING

    Huddinge, Stockholm County, 141 57, Sweden

  • King Chulalongkorn Memorial Hospital

    RECRUITING

    Bangkok, 10330, Thailand

  • King's College Hospital

    RECRUITING

    London, SE5 9RS, United Kingdom

  • Kyungpook National University Hospital

    RECRUITING

    Daegu, 41944, South Korea

  • Linkou Chang Gung Memorial Hospital

    RECRUITING

    Taoyuan City, 333, Taiwan

  • London Health Sciences Centre

    RECRUITING

    London, Ontario, N6A 4L6, Canada

  • Los Angeles Cancer Network

    RECRUITING

    Glendale, California, 91206, United States

  • Maggiore Polyclinic Hospital, Foundation IRCCS Ca' Granda

    RECRUITING

    Milan, 20122, Italy

  • Maharaj Nakorn Chiangmai Hospital

    RECRUITING

    Chiang Mai, 50200, Thailand

  • Marien Hospital Duesseldorf GmbH, Clinic for Oncology, Hematology and Palliative Medicine

    RECRUITING

    Düsseldorf, North Rhine-Westphalia, 40479, Germany

  • Maryland Oncology Hematolofy

    RECRUITING

    Columbia, Maryland, 21044, United States

  • Mater Misericordiae University Hospital

    RECRUITING

    Dublin, D07 R2WY, Ireland

  • Max Super Speciality Hospital Vaishali (A Unit Of Crosslay Remedies Ltd.)

    NOT_YET_RECRUITING

    Ghaziabad, Uttar Pradesh, 201012, India

  • Medanta the Medicity

    RECRUITING

    Gurgaon, 122018, India

  • Mersin Medicalpark Hospital

    NOT_YET_RECRUITING

    Mersin, 33200, Turkey (Türkiye)

  • MidAmerica Cancer Care

    RECRUITING

    Kansas City, Missouri, 64132, United States

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

  • Mor Kaposi General Hospital, Department of Hematology

    RECRUITING

    Kaposvár, H-7400, Hungary

  • Multiprofile Hospital for Active Treatment - Sofia, part of Military Medical Academy, Clinic of Hematology

    RECRUITING

    Sofia, 1606, Bulgaria

  • NRS Medical College and Hospital

    RECRUITING

    Kolkata, West Bengal, 700014, India

  • National Cheng Kung University Hospital

    RECRUITING

    Tainan, 704302, Taiwan

  • National Institute of Neoplastic Diseases

    NOT_YET_RECRUITING

    Lima, 15038, Peru

  • National Taiwan University Hospital

    RECRUITING

    Taipei, 100225, Taiwan

  • Nicolaus Copernicus Provincial Multispecialty Oncology and Traumatology Center in Lodz, General Hematology Unit

    RECRUITING

    Lodz, 93-513, Poland

  • Northwell Health

    NOT_YET_RECRUITING

    Lake Success, New York, 11042, United States

  • Norton Cancer Institute

    RECRUITING

    Louisville, Kentucky, 40207, United States

  • Nottingham City Hospital

    RECRUITING

    Nottingham, NG5 1PB, United Kingdom

  • Nova Scotia Health Authority, Centre for Clinical Research

    RECRUITING

    Halifax, Nova Scotia, B3H 1V7, Canada

  • Novant Health-Cancer Institute

    RECRUITING

    Winston-Salem, North Carolina, 27013, United States

  • Ondokuz Mayis University School of Medicine, Department of Hematology

    RECRUITING

    Samsun, 55139, Turkey (Türkiye)

  • Peter MacCallum Cancer Center

    RECRUITING

    Parkville, Victoria, 3000, Australia

  • Poitiers University Hospital Center - Miletrie Site

    RECRUITING

    Poitiers, 86000, France

  • Polyclinic San Matteo, IRCCS, Department of Oncohematology, Operative Unit of Hematology

    RECRUITING

    Pavia, 27100, Italy

  • Pontifical University Of Rio Grande Do Sul (PUCRS) - St. Luke Hospital

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90610-000, Brazil

  • Porto Alegre Clinical Hospital (HCPA)

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90035-903, Brazil

  • Portuguese Charity of Sao Paulo, Clinical Hematology / Oncology Center

    RECRUITING

    São Paulo, 01323-900, Brazil

  • Pratia Oncology Katowice

    RECRUITING

    Katowice, 40-519, Poland

  • Pratia Onkologia Wroclaw

    NOT_YET_RECRUITING

    Wroclaw, Lower Silesian Voivodeship, 50-019, Poland

  • Pratia Poznan

    NOT_YET_RECRUITING

    Poznan, Greater, 60-192, Poland

  • Praxis am Volkspark Berlin

    RECRUITING

    Berlin, 10715, Germany

  • Princess Margaret Cancer Centre

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Providence Hematology - Vancouver

    RECRUITING

    Vancouver, British Columbia, V6Z 2A5, Canada

  • Queen Elizabeth Hospital Birmingham

    RECRUITING

    Birmingham, B15 2TH, United Kingdom

  • Rabin Medical Center, Davidoff Cancer Center, Hemato-Oncology Institute

    RECRUITING

    Petah Tikva, 49100, Israel

  • Rajavithi Hospital

    RECRUITING

    Bangkok, 10400, Thailand

  • Rajiv Gandhi Cancer Institute & Research Centre

    NOT_YET_RECRUITING

    Delhi, 110085, India

  • Ramathibodi Hospital

    RECRUITING

    Bangkok, 10400, Thailand

  • Royal Adelaide Hospital

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • SAGA Clinical Research Center SpA

    RECRUITING

    Santiago, 7500653, Chile

  • Sahlgrenska University Hospital

    NOT_YET_RECRUITING

    Gothenburg, VG, 41345, Sweden

  • Saint-Louis Hospital

    RECRUITING

    Paris, 75010, France

  • Sakarya University Medical Faculty Hospital

    NOT_YET_RECRUITING

    Sakarya, 54290, Turkey (Türkiye)

  • Samsung Medical Center

    RECRUITING

    Seoul, 06351, South Korea

  • Santa Casa of Mercy of Santos

    RECRUITING

    São Paulo, 11075-900, Brazil

  • Sao Jose do Rio Preto Regional Faculty of Medicine Foundation

    RECRUITING

    São José do Rio Preto, São Paulo, 15090-000, Brazil

  • Sarah Cannon Research Institute (SCRI)

    RECRUITING

    London, W1G 6AD, United Kingdom

  • Semmelweis University, Department of Internal Medicine and Haematology, Division of Hematology

    RECRUITING

    Budapest, H-1088, Hungary

  • Seoul National University Hospital

    RECRUITING

    Seoul, 03080, South Korea

  • Skane University Hospital - Lund, Department of Hematology and Vascular Disorders

    RECRUITING

    Lund, 221 85, Sweden

  • Smilow Cancer Hospital at Yale-New Haven

    RECRUITING

    New Haven, Connecticut, 06511, United States

  • Soon Chun Hyang University Hospital Seoul

    RECRUITING

    Seoul, 04401, South Korea

  • South Tyneside and Sunderland Foundation Trust

    NOT_YET_RECRUITING

    Sunderland, Tyne and Wear, SR4 7TP, United Kingdom

  • Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Clinic of Hematology

    RECRUITING

    Sofia, 1797, Bulgaria

  • St James's University Hospital

    RECRUITING

    Leeds, LS9 7TF, United Kingdom

  • St Vincent's Hospital (Melbourne) Ltd

    RECRUITING

    Fitzroy, Victoria, 3065, Australia

  • St Vincent's University Hospital (SVUH)

    RECRUITING

    Dublin, DO4 T6F4, Ireland

  • Sunnybrook Research Institute, Odette Cancer Center

    RECRUITING

    Toronto, Ontario, M4N 3M5, Canada

  • Szabolcs-Szatmar-Bereg County Teaching Hospital, Department of Hematology

    RECRUITING

    Nyíregyháza, 4400, Hungary

  • Taichung Veterans General Hospital

    RECRUITING

    Taichung, 407219, Taiwan

  • Tallaght University Hospital

    RECRUITING

    Dublin, D24 NR0A, Ireland

  • Tata Medical Center, Kolkata

    RECRUITING

    Kolkata, West Bengal, 700156, India

  • Tata Memorial Centre

    NOT_YET_RECRUITING

    Mumbai, Maharashtra, 400012, India

  • Tennessee Cancer Specialists

    RECRUITING

    Knoxville, Tennessee, 37909, United States

  • Texas Oncology Gulf Coast

    RECRUITING

    The Woodlands, Texas, 77380, United States

  • Texas Oncology Northeast Texas

    RECRUITING

    Denison, Texas, 75020, United States

  • The Canberra Hospital

    NOT_YET_RECRUITING

    Garran, Australian Capital Territory, 2605, Australia

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    RECRUITING

    Seoul, 06591, South Korea

  • The Christie NHS Foundation Trust

    RECRUITING

    Manchester, M20 4BX, United Kingdom

  • The Newcastle Upon Tyne University Hospitals Foundation Trust

    NOT_YET_RECRUITING

    High Heaton, Tyne and Wear, NE7 7DN, United Kingdom

  • The Tel Aviv Sourasky Medical Center, Department of Hematology and Bone Marrow Transplantation, Leukemia Service

    RECRUITING

    Tel Aviv, 6423906, Israel

  • Townsville University Hospital

    RECRUITING

    Douglas, Queensland, 4814, Australia

  • Tranquil Research

    RECRUITING

    Webster, Texas, 77598-4085, United States

  • U.T. MD Anderson Cancer Center, Division of Cancer Medicine

    RECRUITING

    Houston, Texas, 77030, United States

  • UC San Diego Moores Cancer Center

    RECRUITING

    La Jolla, California, 92037, United States

  • Universitatsspital Zurich, Klinik fur Medizinische Onkologie und Hamatologie

    NOT_YET_RECRUITING

    Zurich, 8091, Switzerland

  • University Clinic of Hematology, Oncology and Cell Therapy

    NOT_YET_RECRUITING

    Magdeburg, Saxony-Anhalt, 39120, Germany

  • University Clinical Hospital of Salamanca, Department of Hematology

    RECRUITING

    Salamanca, Castille and León, 37007, Spain

  • University Hospital Brno, Clinic of Internal Medicine - Hematology and Oncology

    NOT_YET_RECRUITING

    Brno, 625 00, Czechia

  • University Hospital Bronn

    NOT_YET_RECRUITING

    Bonn, North Rhine-Westphalia, 53127, Germany

  • University Hospital Foundation Jimenez Diaz

    RECRUITING

    Madrid, Madrid, 28040, Spain

  • University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology

    RECRUITING

    Halle, Saxony-Anhalt, 06120, Germany

  • University Hospital Hradec Kralove, 4th Internal Clinic of Hematology

    RECRUITING

    Hradec Králové, 500 05, Czechia

  • University Hospital Kralovske Vinohrady, Clinic of Internal Hematology

    RECRUITING

    Prague, 100 00, Czechia

  • University Hospital Leipzig, Clinic and Policlinic for Internal Medicine I Haematology and Stem Cell Therapy, Medical Oncology, Haemostaseology

    RECRUITING

    Leipzig, Saxony, 04103, Germany

  • University Hospital Limerick

    NOT_YET_RECRUITING

    Limerick, V94 F858, Ireland

  • University Hospital Ostrava and Faculty of Medicine, University of Ostrava

    NOT_YET_RECRUITING

    Ostrava, 70852, Czechia

  • University Hospital Ramon y Cajal

    RECRUITING

    Madrid, Madrid, 28034, Spain

  • University Hospital Vall d'Hebron, Department of Hematology

    RECRUITING

    Barcelona, Catalonia, 08035, Spain

  • University Hospitals of Leicester

    RECRUITING

    Leicester, Leics, LE1 5WW, United Kingdom

  • University Hosptial Basel

    NOT_YET_RECRUITING

    Basel, Canton of Basel-City, 4031, Switzerland

  • University Multiprofile Hospital for Active Treatment "Sveta Marina", Clinic of Clinical Hematology

    NOT_YET_RECRUITING

    Varna, 9010, Bulgaria

  • University Multiprofile Hospital for Active Treatment "Sveti Ivan Rilski", Sofia, Clinic of Clinical Hematology

    RECRUITING

    Sofia, 1431, Bulgaria

  • University and Polytechnic Hospital La Fe

    RECRUITING

    Valencia, Valencia, 46026, Spain

  • University of Alberta Hospital

    RECRUITING

    Edmonton, Alberta, T6G 2B7, Canada

  • University of Debrecen Clinical Center, Clinic of Internal Medicine, Department of Hematology

    RECRUITING

    Debrecen, 4032, Hungary

  • University of Miami Hospital and Clinics

    RECRUITING

    Miami, Florida, 33136, United States

  • Vanderbilt University Medical Center

    RECRUITING

    Nashville, Tennessee, 37232, United States

  • Vilnius University Hospital Santaros Klinikos

    RECRUITING

    Vilnius, LT-08406, Lithuania

  • Westmead Hospital

    RECRUITING

    Sydney, New South Wales, 2145, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.